Cargando…

Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging

OBJECTIVE: To evaluate response rates at week 16 with ixekizumab in patients with radiographic axial SpA (r-axSpA) and elevated or normal/low baseline inflammation measured by serum CRP or spinal MRI using data from two randomized, double-blind, placebo (PBO)-controlled phase III trials. METHODS: Bi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maksymowych, Walter P, Bolce, Rebecca, Gallo, Gaia, Seem, Emily, Geneus, Vladimir J, Sandoval, David M, Østergaard, Mikkel, Tada, Kurisu, Baraliakos, Xenofon, Deodhar, Atul, Gensler, Lianne S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629340/ https://www.ncbi.nlm.nih.gov/pubmed/35188180 http://dx.doi.org/10.1093/rheumatology/keac104

Ejemplares similares

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
por: Dougados, Maxime, et al.
Publicado: (2020)

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
por: Braun, Jürgen, et al.
Publicado: (2022)

The role of ixekizumab in non-radiographic axial spondyloarthritis
por: San Koo, Bon, et al.
Publicado: (2021)

Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results
por: Deodhar, Atul A., et al.
Publicado: (2021)

Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis
por: Tsiami, Styliani, et al.
Publicado: (2022)

Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial
por: Deodhar, Atul, et al.
Publicado: (2020)

Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52‐Week, Randomized, Controlled Trial
por: Walsh, Jessica A., et al.
Publicado: (2022)

Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks
por: Deodhar, Atul, et al.
Publicado: (2021)

Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials
por: van der Horst-Bruinsma, Irene E., et al.
Publicado: (2022)

Certolizumab Pegol Efficacy in Patients With Non‐Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C‐Reactive Protein Status: An Analysis From the C‐axSpAnd Study
por: Robinson, Philip C., et al.
Publicado: (2022)

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study
por: Landewé, Robert B M, et al.
Publicado: (2023)

Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap
por: Deodhar, Atul, et al.
Publicado: (2019)

The Role of Imaging in Diagnosing Axial Spondyloarthritis
por: Khmelinskii, Nikita, et al.
Publicado: (2018)

Management of Axial Spondyloarthritis – Insights into Upadacitinib
por: Braun, Jürgen, et al.
Publicado: (2022)

JAK Inhibitors for the Treatment of Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2023)

Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Coxitis in axial spondyloarthritis: the unmeasured, yet functionally most important, radiographic progression
por: Rocha, Francisco Airton Castro, et al.
Publicado: (2021)

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
por: Deodhar, Atul, et al.
Publicado: (2023)

A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2019)

COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis
por: Deodhar, Atul, et al.
Publicado: (2022)

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

Use and Switching of Biologic Therapy in Patients with Non-Radiographic Axial Spondyloarthritis: A Patient and Provider Survey in the United States
por: Deodhar, Atul, et al.
Publicado: (2020)

Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?
por: Baraliakos, X, et al.
Publicado: (2015)

Good construct validity of the CT Syndesmophyte Score (CTSS) in patients with radiographic axial spondyloarthritis
por: Stal, Rosalinde, et al.
Publicado: (2023)

Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis
por: Mease, Philip, et al.
Publicado: (2019)

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
por: Braun, Jürgen, et al.
Publicado: (2021)

Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time
por: Baraliakos, Xenofon, et al.
Publicado: (2017)

Anti-CD74 IgA autoantibodies in radiographic axial spondyloarthritis: a longitudinal Swedish study
por: Do, Lan, et al.
Publicado: (2020)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study
por: Kishimoto, Mitsumasa, et al.
Publicado: (2021)

Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
por: Braun, Juergen, et al.
Publicado: (2023)

The FAt Spondyloarthritis Spine Score (FASSS): development and validation of a new scoring method for the evaluation of fat lesions in the spine of patients with axial spondyloarthritis
por: Pedersen, Susanne Juhl, et al.
Publicado: (2013)

Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials
por: Kavanaugh, Arthur, et al.
Publicado: (2023)

Serum granulocyte-macrophage colony-stimulating factor (GM-CSF) is increased in patients with active radiographic axial spondyloarthritis and persists despite anti-TNF treatment
por: Papagoras, Charalampos, et al.
Publicado: (2022)

Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey
por: Hunter, Theresa, et al.
Publicado: (2021)

Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
por: Braun, Jürgen, et al.
Publicado: (2021)

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials
por: Genovese, Mark C, et al.
Publicado: (2020)

Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE
por: Landewé, Robert, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cjrgpjq6bh0lf6is193r7ribuu